The fourteen analysts currently covering Denali Therapeutics INC (NASDAQ: DNLI) have reportedly given the company a rating of “buy,” which reflects the consensus opinion of those analysts, as reported by Bloomberg Ratings.

There have been thirteen unique research specialists who have suggested to investors that they should buy the stock. $54.58 is the average price target for one year that analysts who rated the stock in the previous year have assigned to the stock as a price target for stock.

On Monday, February 27, the public received Denali Therapeutics (NASDAQ: DNLI) quarterly earnings report.

The report was distributed to them electronically.

The company announced $0.75 per share for the period, which is $0.02 higher than the average $0.77 per share forecast.

The sales for the company’s most recent quarter came in at $10.28 million, significantly lower than the general average projection of $11.29 million.

Denali Therapeutics had a negative return on equity, measuring 35.67%, and a negative net margin, measuring 300.55%.

Both of these metrics were negative for the company.

The quarterly revenue that was reported by Denali Therapeutics was 17.8 percentage points lower than what it had been during the same period the previous year. Compared to the previous year’s results for the same quarter, the company’s earnings per share came in at $0.62.

This year, revenue for each share of Denali Therapeutics is expected to come in at $3.31, according to projections made by industry analysts.
When trading started on Tuesday, the price of a share of Denali Therapeutics was $27.16.

This corporation has a price-to-earnings ratio of -10.45, a beta value of 1.39, and a market capitalization of $3.71 billion.

The stock’s moving averages for the last 50 and 200 days are currently at $29.16 and $29.60, respectively.

Denali Therapeutics hit a high of $39.43 during its 52-week trading period and a low of $20.24 during that same period.
It has been brought to the attention of the research community by several market watchers and analysts that their opinions concerning the stock have been shared. On Monday, December 5, after the market had opened, Cowen began covering shares of Denali Therapeutics and assigned the company the “outperform” rating, which is a very optimistic assessment of the company’s future. Oppenheimer published a study on Thursday, March 2, in which they lowered their price target for Denali Therapeutics shares from $85.00 to $70.00.

The new target price can be found here.

The report additionally assigned the company the rating of “outperform” for its performance.

After the stock market opened for business on Monday, December 5, Cowen began providing coverage for shares of Denali Therapeutics.

They gave the company an “outperform” rating, which is encouraging for its future.

In a report on February 28, Wedbush lowered its price target on Denali Therapeutics shares from $46.00 to $38.00.

The previous price target was $46.00.

In addition to that, they gave the business an “outperform” rating. Stifel Nicolaus lowered their price objective on Denali Therapeutics shares from $36.00 to $32.00 in the report they issued on Thursday, March 2.

The previous price objective was $36.00.

This was the third and final adjustment that was made.

According to additional Denali Therapeutics news, Ryan J. Watts, Chief Executive Officer of Denali Therapeutics, sold 33,815 shares on Monday, February 13. When the shares were finally put up for sale, they brought in a total of $1,017,155.20, corresponding to an average price of $30.08 per share.

Buyers were willing to spend this amount.

The chief executive officer has a direct ownership stake in the company equal to 2,239,913 shares, currently valued at approximately $67,376,583.04 at the current market price. You will be able to acquire additional information regarding the transaction if you click on the link that has been provided for you.

This link will take you to an official Securities and Exchange Commission document.

According to additional Denali Therapeutics news, Ryan J. Watts, Chief Executive Officer of Denali Therapeutics, sold 33,815 shares on Monday, February 13. When the shares were finally put up for sale, they brought in a total of $1,017,155.20, corresponding to an average price of $30.08 per share.

Buyers were willing to spend this amount.

The chief executive officer currently holds a direct ownership stake in 2,239,913 company shares, estimated to have a value of approximately $67,376,583.04. You will be able to acquire additional information regarding the transaction if you click on the link that has been provided for you.

This link will take you to an official Securities and Exchange Commission document.

In addition, Carole Ho, an executive the company previously employed, sold 2,913 shares on January 4.

The stock was sold for a total value of $83,573.97, with each share fetching an average price of $28.69 when offered for sale. Following the successful completion of the transaction, the corporate insider now owns 175,500 company shares, which have a combined value of $5,035,095.

This is where you may see the disclosure that pertains to the sale. Over the previous three months, business insiders have offloaded 91,020 shares of company stock, bringing in a total of $2,689,975 in proceeds.

The company’s management and employees collectively own a stake in the business equal to 12.70% of the total value.

Most recently, various institutional investors, including hedge funds and other investment vehicles, have modified the processes by which they invest in the company.

In the second quarter, Creative Planning increased the percentage of Denali Therapeutics stock is owned by 4.4%.

The company increased its total number of stock shares to 7,075 during the most recent quarter by purchasing an additional 295.

The current market value of the company’s stock is $208,000.

Amalgamated Bank increased the amount of Denali Therapeutics stock owned by 2.4% during the third quarter.

Amalgamated Bank now has 380 shares of the company’s stock thanks to the purchase of 15,942 additional shares at a total cost of $480,000 during the most recent fiscal quarter.

During the final three months of 2018, Exchange Traded Concepts LLC was able to amass an additional 18.8 percent of Denali Therapeutics stock, bringing the total percentage of the company’s stock it owned to 58.8 percent.

Exchange Traded Concepts LLC now has 2,584 shares in the company, having purchased an additional 408 in the most recent quarter to bring its total number of shares to 2,584.

The current value of these shares is 72 thousand dollars.
Due to the investment firm’s recent purchase, Rhumbline Advisers’ holdings in Denali Therapeutics increased by 0.5 percent during the first three months of the year. Following the acquisition of 496 additional shares during the most recent fiscal quarter, Rhumbline Advisers now directly owns 97,145 shares of the company’s stock, which have a combined value of $3,125,000.

This brings the total number of shares directly owned by the firm to 98,145.

Last but certainly not least, during the third quarter, Rockefeller Capital Management L.P.

Increased the amount of Denali Therapeutics stock it invested by 5.4%.

As a result of the purchase of 604 additional shares during the most recent quarter, Rockefeller Capital Management L.P. now directly owns 11,834 shares in the company.

Based on the current market price, this number of shares equals $362,000 in today’s money.

At present, institutional investors own 67.26 percent of the equity in the company.

The post Brokerages have assigned a consensus rating of “Buy” to Denali Therapeutics Inc. (NASDAQ:DNLI). appeared first on Best Stocks.